Lucid Diagnostics (LUCD) Q4 2025 earnings summary

Executive summary

• Q4 2025 EsoGuard test volume reached 3,664, a 29% sequential increase, generating $1.5 million in revenue and surpassing the target range.

• Awarded a U.S. Department of Veterans Affairs contract for EsoGuard, expanding access to 170 VA medical centers serving approximately nine million veterans.

• Positive real-world data from nearly 12,000 at-risk patients confirmed high technical success, safety, and rapid procedure times for EsoGuard and EsoCheck.

• Significant progress in commercial payer engagement, including UnitedHealthcare and laboratory benefit managers (LBMs), with updated EGD guidelines supporting broader adoption.

• Focus for 2026 includes converting demand into revenue, deepening VA relationships, expanding health system adoption, and advancing commercial and Medicare coverage.

Financial highlights

• Q4 2025 revenue was $1.5 million, up from $1.2 million in Q4 2024; full-year revenue rose to $4.7 million from $4.3 million.

• Cash and cash equivalents at year-end 2025 were $34.7 million, up from $22.4 million a year earlier.

• Q4 2025 GAAP net loss attributable to common stockholders was $16.3 million, or $(0.12) per share; non-GAAP adjusted loss was $12.6 million, or $(0.10) per share.

• Non-GAAP operating expenses rose to $48.7 million in 2025 from $44.3 million in 2024, mainly due to increased sales and market access staffing.

• Senior secured convertible notes increased to $24.0 million from $18.6 million year-over-year.

Outlook and guidance

• Anticipates imminent Medicare coverage, which would retroactively cover claims up to one year prior.

• Expanded reimbursement and coverage pathways, including CMS and multi-payor coverage, are expected to support future growth.

• Ongoing efforts to secure additional commercial payer and LBM coverage, with positive developments expected in coming quarters.

• Implementation of EsoGuard in the VA healthcare system positions the company for broader adoption.

• Focus for 2026 is on revenue growth, expanded coverage, and deepening relationships with VA and health systems.